The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -10.66 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2024, as Tvardi Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Other Revenue Non Cash$4.3M
- Other Revenue$4.3M
- Collaborative Revenue$2.1M
- Other Non Cash Revenue$1.5M
- Commercial Supply Revenue$640K
Leadership changes
From Tvardi Therapeutics, Inc.'s own filings, the day they're filed.
- Shaheen Wirk · member · departureeff. 2025-07-08
- K. Helen M. Boudreau · appointment
- Covered Termination · departure
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-07-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Tvardi Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Tvardi Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.